Financial Analysis: Oncotelic Therapeutics (OTCMKTS:OTLC) versus Lexicon Pharmaceuticals (NASDAQ:LXRX)

Oncotelic Therapeutics (OTCMKTS:OTLC) and Lexicon Pharmaceuticals (NASDAQ:LXRX) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, valuation, earnings, analyst recommendations, institutional ownership, profitability and risk.

Profitability

This table compares Oncotelic Therapeutics and Lexicon Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Oncotelic Therapeutics	N/A	-22.16%	-6.17%
Lexicon Pharmaceuticals	-101.08%	-41.94%	-22.03%

Earnings and Valuation

This table compares Oncotelic Therapeutics and Lexicon Pharmaceuticals”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oncotelic Therapeutics	$70,000.00	206.40	-$4.52 million	N/A	N/A
Lexicon Pharmaceuticals	$49.80 million	14.38	-$50.34 million	($0.14)	-12.07

Oncotelic Therapeutics has higher earnings, but lower revenue than Lexicon Pharmaceuticals.

Volatility & Risk

Oncotelic Therapeutics has a beta of -0.56, meaning that its stock price is 156% less volatile than the S&P 500. Comparatively, Lexicon Pharmaceuticals has a beta of 0.94, meaning that its stock price is 6% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current ratings and price targets for Oncotelic Therapeutics and Lexicon Pharmaceuticals, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oncotelic Therapeutics	0	0	0	0	0.00
Lexicon Pharmaceuticals	1	0	2	0	2.33

Lexicon Pharmaceuticals has a consensus price target of $4.15, suggesting a potential upside of 145.56%. Given Lexicon Pharmaceuticals’ stronger consensus rating and higher probable upside, analysts clearly believe Lexicon Pharmaceuticals is more favorable than Oncotelic Therapeutics.

Institutional & Insider Ownership

74.7% of Lexicon Pharmaceuticals shares are held by institutional investors. 39.2% of Oncotelic Therapeutics shares are held by company insiders. Comparatively, 13.9% of Lexicon Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

About Oncotelic Therapeutics

Oncotelic Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing drugs for the treatment of orphan oncology indications. The company's lead product candidate is OT-101, an antisense against TGF-ß2, which is in phase 3 clinical trials for pancreatic cancer and glioblastoma, as well as develops OT-101 for the treatment of various viruses, including severe acute respiratory syndrome and coronavirus. It also develops OXi4503 for the treatment of acute myeloid leukemia and myelodysplastic syndromes; and CA4P for the treatment of advanced metastatic melanoma; intranasal drug and delivery system for intra-nasal Apomorphine for the treatment of Parkinson's Disease, erectile disfunction, and female sexual disfunction; Artemisinin, a natural derivative from an Asian herb Artemisia Annua; and AI based technologies to enhance the development and commercialization of Artemisinin based products and support technologies. Oncotelic Therapeutics, Inc. is based in Agoura Hills, California.

About Lexicon Pharmaceuticals

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract. Lexicon Pharmaceuticals, Inc. has strategic collaboration and license agreements with Bristol-Myers Squibb Company and Genentech, Inc. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.